The multitargeted molecular docking results consistently demonstrated strong binding affinities between 3-1-BCMIYPPA and crucial target proteins implicated in lung cancer progression, including CDK2, SRC-2 domains of C-ABL, EGFR, and IGF-1R and the robust interactions suggest the compound can effectively modulate the activity of these proteins, play pivotal roles in lung cancer development and growth. The gene discussed is SRC; the disease is lung carcinoma.